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Specifi  c targets of cellular immunity in human premalignancy are largely unknown. Mono-
clonal gammopathy of undetermined signifi  cance (MGUS) represents a precursor lesion to 
myeloma (MM). We show that antigenic targets of spontaneous immunity in MGUS differ 
from MM. MGUS patients frequently mount a humoral and cellular immune response against 
SOX2, a gene critical for self-renewal in embryonal stem cells. Intranuclear expression of 
SOX2 marks the clonogenic CD138− compartment in MGUS. SOX2 expression is also de-
tected in a proportion of CD138+ cells in MM patients. However, these patients lack anti-
SOX2 immunity. Cellular immunity to SOX2 inhibits the clonogenic growth of MGUS cells 
in vitro. Detection of anti-SOX2 T cells predicts favorable clinical outcome in patients with 
asymptomatic plasmaproliferative disorders. Harnessing immunity to antigens expressed by 
tumor progenitor cells may be critical for prevention and therapy of human cancer.
The immune system has long been debated as a 
potential barrier to carcinogenesis and may 
provide a valuable approach to early detection 
and prevention of cancer (1). Studies have doc-
umented the ability of the immune system to 
respond to antigens expressed by tumor cells in 
cancer patients (2). However, the specifi  c nature 
of antigenic targets of T cell immunity in hu-
man premalignancy is largely unknown (3, 4). 
Understanding the specifi  c targets of immune 
recognition of the earliest human tumors and 
their precursors directly in patients is therefore 
a critical fi  rst step for harnessing the immune 
system to detect and prevent human cancer. 
Monoclonal gammopathy of undetermined sig-
nifi  cance (MGUS) occurs in 3% of the popula-
tion >50 yr of age and represents a precursor 
lesion to myeloma (MM) (5). Tumor cells in 
MGUS carry most of the known cytogenetic 
and genomic abnormalities found in MM (6), 
but only a small proportion transform into clin-
ical malignancy, suggesting a role for additional 
events, including those involving the host, in 
regulating malignant transformation.
Studies have recently provided experimental 
evidence for the concept that the growth of 
several human tumors may depend on a small 
proportion of clonogenic or “cancer stem cells” 
(7). Although the bulk tumor in MM consists 
of plasma cells that express syndecan-1 (CD138), 
recent studies have suggested that the clonogenic 
growth may be enriched in a fraction missing 
this marker (8, 9). However, specifi  c markers to 
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Figure 1.  Antibody responses in patients with monoclonal gammo-
pathies. (A) Preabsorbed serum samples from patients with MGUS, 
AMM, and MM were evaluated by SADA for the presence of IgG anti-
bodies against a panel of 83 SEREX-defi  ned antigens. The frequency 
of antibody responses within the cohorts of patients with asymptom-
atic plasma cell disease and multiple MM is shown. Numbers indicate 
the patients with positive antibody response out of absolute numbers 
of patients evaluated by SADA for each group. (B, left) Patterns of 
antigenic reactivity in patients with MGUS, MM, and AMM. Rows 
depict individual patients according to their diagnosis, and columns 
show antibody reactivity against 23 tumor antigens with seropositivity 
in this cohort. Specifi  c antigens in each column correspond numerically 
to antigens 1–23 in Table S2. (right) Shown are specific antigens 
inducing differential antibody response between subgroups of mono-
clonal gammopathies and the frequency of antibody reactivity as 
  detected by SADA. *, P < 0.05. PRPF31, pre-mRNA–processing factor 
31 homologue; RNPC1, RNA-binding region (RNP1, RRM)–containing 1. 
(C) ELISA for detection of SOX2-specifi  c (left) and EBNA EBV–specifi  c 
(middle) IgG antibodies in sera of MGUS, AMM, and MM patients. 
The distribution of antibody titers within specifi  c groups is shown. 
(right) Overall SOX2 reactivity. Dotted lines represent the cutoff 
values for seropositivity. *, P < 0.05. (D) Titers of SOX2 antibodies in 
serial dilutions of sera from SOX2-reactive patients. (E) Sera from 
SOX2-positive patients were absorbed on SOX2-coated plates (or 
NY-ESO1–coated plates as irrelevant controls) and evaluated for anti-
SOX2 IgG (or anti-EBNA IgG as a control) antibodies by ELISA (left) 
or detection of monoclonal Ig (by serum protein electrophoresis). 
Prior absorption on SOX2-abrogated anti-SOX2 reactivity without 
affecting anti-EBNA IgG reactivity (left) and mono  clonal paraprotein 
concentration (right) are shown. Absorption on NY-ESO1 protein was JEM VOL. 204, April 16, 2007  833
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identify this population are lacking. Whether the immune 
system has the capacity to specifi   cally target antigens ex-
pressed on cancer stem cells in humans is also not known.
In this paper, we show that the expression of an embryo-
nal stem cell marker, SOX2, specifi  cally marks the clonogenic 
CD138− compartment in MGUS patients, and these patients 
frequently mount humoral and cellular immunity to this 
  antigen. These data demonstrate the capacity of the human 
immune system to spontaneously target antigens expressed on 
tumor progenitors and the association of spontaneous immu-
nity against this target with an improved clinical outcome.
RESULTS
Detection of anti-SOX2 IgG antibodies in MGUS but not 
MM patients or healthy donors
In prior studies, we have shown that the immune system is 
capable of recognizing the preneoplastic lesions in MGUS 
(10). To begin a systematic analysis of antigenic targets of 
  antitumor immunity in MGUS/MM, we initially analyzed 
sera from patients with MM (n = 35), MGUS (n = 28), and 
asymptomatic MM (AMM; n = 14) for the presence of IgG 
antibodies against a panel of 83 serological expression of 
cDNA expression libraries (SEREX)–defi  ned tumor antigens 
using a serum antibody detection array (SADA; Fig. 1 A and 
Table S1, available at http://www.jem.org/cgi/content/full/
jem.20062387). Reactivity against 23 of the antigens in this 
panel was detected in the sera from MGUS, AMM, or MM 
patients but only in 1 out of 27 sera from normal blood donors 
with this assay. Interestingly, the pattern of antigenic reactivity 
diff  ered between these cohorts (Fig. 1 B and Table S2). Im-
mune responses to Sry-HMG-box 2 (SOX2) protein were 
seen only in MGUS, whereas antibodies against certain other 
antigens (DNA methyltransferase 3, synaptonemal complex 
protein 1, and kinesin family member 15) were only detected 
in AMM (Fig. 1 B). To validate and quantify the presence of 
anti-SOX2 antibodies in MGUS, we reanalyzed a larger 
  cohort of patients and age-matched healthy controls with an 
ELISA-based assay (Fig. 1 C). Overall, anti-SOX2 IgG anti-
bodies were detected in 12 out of 52 (23%) MGUS patients 
but in none of the AMM (n = 23) and MM (n = 40) patients 
and in only 1 out of 92 healthy donors tested (P < 0.001). As 
controls, immune responses to Epstein-Barr nuclear antigen 1 
(EBNA-1; Fig. 1 C) and tetanus toxoid (not depicted) were 
comparably detectable in all cohorts. Anti-SOX2 antibodies 
were present at a high titer and were detectable at a dilution 
of ≥1:400 (Fig. 1 D). No anti-SOX2 IgM antibodies were 
detected in any cohort (unpublished data). Anti-SOX2 IgG 
antibodies were of both κ and λ light chain specifi  city and 
were detected in both IgG and non-IgG gammopathies 
  (unpublished data). Preabsorption of sera with recombinant 
SOX2 protein abrogated anti-SOX2 reactivity without af-
fecting the monoclonal paraprotein (Fig. 1 E). Therefore, the 
observed reactivity is not caused by the monoclonal Ig found 
in these patients. For six MGUS patients with high titers of 
anti-SOX2 antibodies, follow-up samples over 2 yr revealed 
that the antibody titers, as well as the clinical status, remain 
stable over time (Fig. 1 F). In all SOX2-reactive MGUS 
sera, antibodies were predominantly of the IgG1 subclass 
(Fig. 1 G). Collectively, these data demonstrate the presence 
of anti-SOX2 IgG1 antibodies in a substantial proportion of 
MGUS patients.
Detection of anti-SOX2 T cell responses in MGUS 
but not MM patients or healthy donors
We examined if SOX2 was also a target of antitumor T cell 
response in these patients. Freshly isolated PBMCs were 
stimulated with a library of overlapping 15-mer peptides 
spanning the entire SOX2 protein (Table S3, available at 
http://www.jem.org/cgi/content/full/jem.20062387/DC1). 
Peptide-reactive chemokine production (IFN-γ–inducible 
protein 10 [IP-10]) was monitored by Luminex analysis. 
  Using this assay, SOX2-specifi  c T cells were detected in fresh 
PBMCs from 11 out of 16 MGUS patients tested but in none 
of the MM patients (n = 14) or healthy donors (n = 20; P < 
0.05; Fig. 2, A and B). Anti-SOX2–specifi  c T cells were also 
detected in 2 out of 21 patients with AMM. T cell reactivity 
against a pool of MHC class I–restricted viral antigen peptides 
(CEF, derived from CMV, EBV, and infl  uenza virus) was 
comparable in all four cohorts. SOX2-specifi  c T cells were 
detected in both blood and bone marrow in four patients 
tested (Fig. 2 B). In this assay, the production of IP-10, a po-
tent antiangiogenic chemokine, in response to viral or SOX2 
peptides is a sensitive readout for T cell–derived IFN-γ, as it 
is abrogated by prior depletion of CD3+ T cells and sub-
stantially reduced in the presence of neutralizing anti–IFN-γ 
mAb (Fig. 2 C). SOX2-specifi  c reactivity in MGUS patients 
targeted peptides in pools 3 or 4 of the SOX2 peptide library. 
In two patients, SOX2-specifi  c T cells were detected in 
  response to both pools 3 and 4 (Fig. 2 D). SOX2-reactive 
T cells detected in this assay were predominantly MHC class I 
restricted, as the response was inhibited by anti–MHC class I 
blocking antibody (Fig. 2 E). To further analyze the nature of 
this T cell response, PBMCs from MGUS patients were 
stimulated for 2 wk with autologous DCs loaded with the 
SOX2 peptide library and analyzed for the presence of 
SOX2-specifi  c T cells by intracellular IFN-γ fl ow cytometry. 
These experiments demonstrated that SOX2-reactive T cells 
included both CD4+ and CD8+ T cells (Fig. 2 F). In con-
trast, SOX2-specifi  c T cells could not be detected from MM 
patients or healthy donors, even after four restimulations with 
peptide-pulsed DCs (Fig. 2 F and not depicted). Expanded 
SOX2-reactive CD4+ T cells were of the Th1 cell phenotype, 
performed as a control. Data represent the mean ± SEM. (F) Long-term 
persistence of anti-SOX2 IgG response in follow-up samples. Titers 
of anti-SOX2–specific IgG antibodies were detected in follow-up 
samples from patients with MGUS (patients 1–6). (G) IgG subclass–
specific analysis of SOX2-specific antibody response in patients 
with MGUS.834  IMMUNITY TO STEM CELLS IN PREMALIGNANCY | Spisek et al.
Figure 2.  Analysis of SOX2-specifi  c T cell responses. (A) Overall 
analysis of frequency of anti-SOX2 T cell responses in patients with 
MGUS, AMM, and MM and healthy donors. (B) Analysis of anti-SOX2 T cell 
reactivity in freshly isolated PBMCs and BMMNCs. Freshly isolated MNCs 
were stimulated with peptide pools derived from the SOX2 peptide library 
for 48 h, and supernatants were analyzed for IP-10 production. Data rep-
resent the mean ± SEM. (C) Depletion of CD3+ T cells or neutralization of 
IFN-γ decreases antigen-specifi  c production of IP-10 in response to viral 
peptides (left) or SOX2-derived peptides (right). (left) PBMCs were stimu-
lated with a cocktail of peptides derived from viral antigens (CEF) with or 
without prior depletion of CD3+ T cells or prior treatment with 10 μg/ml 
anti–IFN-γ blocking antibody or isotype control mAb. (right) PBMCs from 
a MGUS patient were similarly stimulated with four pools of SOX2-
  derived peptides. Supernatants were analyzed for IP-10 production by JEM VOL. 204, April 16, 2007  835
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as they mainly produced IFN-γ, but not IL-4 or IL-10, upon 
SOX2 stimulation (Fig. 2 G). SOX2-specifi  c T cells in 
MGUS were detected in seven out of nine patients with 
positive anti-SOX2 antibodies tested, as well as in four of 
seven patients without detectable anti-SOX2 antibodies. 
Therefore, SOX2 is a frequent target for specifi  c T cell im-
munity in MGUS patients but not in MM or healthy donors, 
and the detection of specifi  c T cell responses may be more 
sensitive than current assays in detecting humoral responses.
Intranuclear SOX2 marks the clonogenic compartment 
in MGUS
Expression of SOX2 is restricted to embryonal and neural 
stem cells, wherein it plays a critical role in regulating the 
self-renewal and pluripotency of stem cells (11–15). Recent 
studies in MM and MGUS have suggested that a minor 
CD138− subpopulation of both MM cell lines and primary 
cells is enriched in clonogenic progenitors, capable of growth 
in methylcellulose as well as in immune-defi  cient mice (8, 9). 
Analysis of intranuclear SOX2 expression in two MM cell 
lines by fl  ow cytometry, as well as SOX2 mRNA by Taq-
Man, revealed that SOX2 indeed specifi   cally marks this 
CD138− subpopulation (Fig. 3, A and B). Analysis of SOX2 
expression in marrow from MGUS patients revealed that 
SOX2+ cells were restricted for tumor-associated Ig light 
chain but lacked the expression of the terminal plasma cell 
diff  erentiation marker CD138 and the hematopoietic stem 
cell marker CD34 (Fig. 3 C). These cells expressed lower 
levels of Ig light chain compared with CD138+ plasma cells 
and lacked expression of CD19, a B cell marker. Overall, 
SOX2+ cells in the MGUS marrow accounted for only 0.5–
1.5% of mononuclear cells (MNCs) and had a phenotype 
consistent with preplasma cells (CD138−CD19−IgLlo) (16). 
Interestingly, in patients with active MM, SOX2+ cells were 
also observed in the more diff  erentiated CD138+IgLhigh com-
partment in fi  ve out of fi  ve patients tested (Fig. 3 D). The 
SOX2 expression pattern in patients with AMM was inter-
mediate, with three out of fi  ve patients resembling the stain-
ing in MGUS (Fig. 3 D), whereas the other two were more 
like MM. Circulating tumor cells in a patient with advanced 
MM in leukemic phase showed higher reactivity, suggesting 
the acquisition of this marker by more diff  erentiated cells in 
some patients with more aggressive disease (Fig. 3 D).
Targeting SOX2 immunity inhibits the clonogenic growth 
of tumors
T cells from HLA-A2+ MGUS patients were capable of IP-10 
secretion in response to a CD138− compartment of A2+ 
U266 cells (wherein the SOX2 expression is limited; Fig. 3 A), 
Luminex. (D) Patterns of anti-SOX2 T cell reactivity in MGUS patients. Gray 
squares represent a positive T cell response against a corresponding pool 
of the SOX2 peptide library. (F) Analysis of anti-SOX2 T cell reactivity in 
PBMCs from two patients with SOX2-specifi  c T cells against SOX2. Stimu-
lation with SOX2 peptides was performed in the presence of anti–MHC 
class I blocking antibody and supernatants analyzed for IP-10 production. 
Data represent the mean ± SEM. (F) Expansion of SOX2-specifi  c CD4 and 
CD8 T cells in MGUS after two stimulations with SOX2 peptide library–
loaded DCs evaluated by intracellular staining for IFN-γ. Representative 
results of one experiment out of three with similar results are shown. 
(G) ELISA for IFN-γ, IL-4, and IL-10 in the supernatants from cultures of 
SOX2-stimulated T lymphocytes.
consistent with the recognition of endogenously presented 
antigen (Fig. 4 A). Although SOX2 is expressed only by a 
proportion of the bulk tumor, immunity against this antigen 
could still be important if this subpopulation or antigen was 
important for the clonogenic growth of tumors. To directly 
test this, marrow MNCs from MGUS patients were stimu-
lated with the SOX2 peptide library, and SOX2 responsive-
ness was documented by the production of IP-10 (Fig. 4 B). 
Marrow MNCs (CD34−CD138−) stimulated under these 
conditions were plated in clonogenic assays (9). Cultures 
stimulated with the SOX2 peptide library demonstrated sub-
stantially inhibited clonogenic growth in three out of three 
MGUS patients tested (Fig. 4 B and not depicted). As noted 
earlier, stimulation of marrow MNCs from MM with SOX2 
peptides did not lead to any detectable reactivity (Fig. 2, A 
and F), and consistent with this, prestimulation with the 
SOX2 peptide library did not lead to inhibition of clono-
genic growth in MM (Fig. 4 C).
Detection of anti-SOX2 T cells predicts a favorable outcome 
in patients with asymptomatic plasmaproliferative disorders
Most studies evaluating the clinical signifi  cance of anti  tumor 
immunity in humans are based on retrospective data. Several 
of the patients analyzed in this study were enrolled in an 
  observational trial of patients with asymptomatic plasmapro-
liferative disorders, performed under the auspices of the South-
west Oncology Group. This provided a unique   opportunity to 
prospectively evaluate whether T cell im  munity to a single 
antigen could predict tumor progression. With a median 
  follow up of 24 mo, patients with anti-SOX2 T cells had a 
signifi  cantly lower net change in the level of tumor-derived 
monoclonal Ig (M spike) over time compared with those 
lacking anti-SOX2 T cells (mean increase in M spike = 0.08 
g/dl vs. 0.63 g/dl, respectively; P < 0.05; Fig. 5 A). The pa-
tients with anti-SOX2 T cells also had a signifi  cantly lower 
likelihood of disease progression, with a 2-yr progression-free 
survival rate of 100 versus 30% compared with patients lacking 
anti-SOX2 T cells. (P < 0.01; Fig. 5 B). Therefore, immunity to 
SOX2 predicts the clinical outcome in patients with asymp-
tomatic plasmapro  liferative disorders.
DISCUSSION
A growing body of evidence points to the capacity of the hu-
man immune system to recognize preneoplastic lesions (3, 4, 
10, 17, 18). However, the nature of specifi  c antigens recog-
nized by T cells in the preneoplastic stage of human cancer is 
largely unknown. The data in this paper suggest that the pattern 
of antigens spontaneously recognized by the immune system 
in preneoplastic lesions may diff  er from that in clinical cancer. 836  IMMUNITY TO STEM CELLS IN PREMALIGNANCY | Spisek et al.
Therefore, these data have implications for harnessing the 
immune system for the early detection and prevention of 
cancer in humans (19, 20).
 The fi  nding (originating from an unbiased search) that 
immunity to SOX2 (a gene critical for the self-renewal and 
pluripotency of embryonic stem cells) (14, 15) predicts clin-
ical outcome supports the importance of stem cell genes and 
self-renewal pathways in cancer biology. These data also 
show that intranuclear SOX2 specifi  cally marks the putative 
MM progenitors (8). SOX2 has also been recently found 
to be expressed in other cancer stem cells and implicated in 
  intestinal metaplasia in gastric cancer (12, 13). Identifi  cation 
of a specifi  c marker for the putative progenitor population   
in MM should facilitate understanding of myelomagenesis, 
as well as the development of specifi  c therapies targeting this 
population. A subpopulation of CD138+ cells also acquires 
the expression of SOX2 in patients with progressive MM. 
Thus, the progression from MGUS to MM may involve the 
acquisition of self-renewal properties by the diff  erentiated 
compartment of the clone. In other words, there may be a 
fundamental diff  erence in the nature of the self-renewing 
compartment in MGUS versus MM. Further studies are 
Figure 3.  Phenotype of SOX2-expressing cells in MM cell lines 
and in patients with MGUS, AMM, and MM. (A) Intranuclear staining 
for SOX2 expression in multiple MM cell lines U266 and cag. Data shown 
are gated on live cells based on scatter properties, and SOX2 expression 
was analyzed by intranuclear staining. The percentage of cells in each 
quadrant is indicated. (B) Analysis of SOX2 mRNA and protein in sorted 
CD138+ and CD138− MM cells. FACS data shown are gated for live cells 
based on scatter properties. Cells were stained with anti-CD138 and 
To-Pro-3 (to further discriminate dying cells) before the cell sort. Live 
(To-Pro-3–negative) cells were then sorted into CD138− and CD138+ 
populations by fl  ow sorting. Each population was stained for the expres-
sion of intranuclear SOX2 expression and analyzed for the expression of 
SOX2 mRNA by TaqMan. The relative quantity of SOX2 transcripts (nor-
malized to GAPDH) is shown. The percentage of cells in each quadrant is 
indicated. (C) SOX2 expression in BMMNCs in a patient with IgG κ MGUS. 
BMMNCs were stained with mAbs against SOX2 in combination with 
other markers. Representative results of one out of eight MGUS patients 
are shown. (D) SOX2 expression patterns in tumor cells from patients with 
AMM, MM, and plasma cell leukemia. Data are representative of fi  ve pa-
tients tested with MM and of seven patients with AMM. Three out of fi  ve 
AMM patients had SOX2 expression patterns similar to MGUS patients 
(AMM). In two out of fi  ve patients with AMM, the pattern was similar to 
that in MM. Clonotypic light chain refers to the light chain of the tumor-
derived monoclonal Ig.JEM VOL. 204, April 16, 2007  837
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needed to evaluate this possibility. Very similar correlations 
have recently been described in patients with chronic my-
elogenous leukemia, wherein blast transformation is associ-
ated with the acquisition of self-renewal genes by the more 
diff  erentiated compartment of the clone (21, 22).
In earlier experiments, we had shown that the tumor bed 
in MGUS is enriched for T cells reactive against autologous 
CD138+ preneoplastic cells (10). The data in the current 
  paper extend these fi  ndings to show that MGUS patients also 
mount an immune response against antigens expressed in the 
CD138− compartment of the clone, thought to be enriched 
in clonogenic tumor progenitors. The frequency of these 
T cells is low (relative to an antiviral responses during acute 
infection), and they target an antigen expressed only in a pro-
portion of the clone. However, stimulation of the marrow 
MNCs with this antigen, without prior in vitro expansion, 
was suffi   cient to inhibit the clonogenic growth of MGUS 
cells in vitro. One possibility is that the immune response 
  focused against progenitors or self-renewal genes may be 
more effi   cient in suppressing clonogenic growth than in 
  immunity against bulk tumor. Interestingly, spontaneous 
  immunity to SOX2 was not detectable in MM patients, who 
also carry SOX2-expressing cells. Further studies are needed 
to understand the absence of spontaneous SOX2 immunity 
in MM patients. Importantly, MGUS patients with anti-SOX2 
Figure 4.  Relevance of SOX2-specifi  c T cells for the recognition of 
tumor cells and inhibition of clonogenic tumor growth. (A) Produc-
tion of IP-10 in HLA-A2+ MGUS patients in response to MACS-sorted 
CD138− and CD138+ subsets of U266 cell line (HLA-A2+). Representative 
results for two patients are shown. (B) Inhibition of clonogenic growth of 
primary tumor cells after stimulation with the SOX2 peptide library in 
MGUS (left). BMMNCs were depleted of CD138+ and CD34+ cells, incu-
bated with SOX2 or control peptides, and plated with 5 × 105 monocyte-
derived DCs/ml at a ratio of 1:2 in Methocult. Colonies were counted by 
microscopy 2–3 wk after plating. Effective prestimulation with SOX2 pep-
tides was documented by IP-10 production 48 h after stimulation (right). 
The relative growth of tumor colonies for two patients with SOX2-reac-
tive T cells is shown. (C) Clonogenic growth of primary tumor cells after 
stimulation with the SOX2 peptide library in MM. BMMNCs were depleted 
of CD138+ and CD34+ cells, incubated with SOX2 or left unstimulated, 
and plated with 5 × 105 monocyte-derived DCs/ml at a ratio of 1:2 in 
Methocult. Colonies were counted by microscopy 2–3 wk after plating. 
Relative growth of tumor colonies for two patients with SOX2-reactive 
T cells is shown. Data represent the mean ± SEM.
Figure 5.  Correlation of detectable SOX2-reactive T cell immunity 
with clinical outcome in patients with asymptomatic plasmaprolif-
erative disorders. (A) Net change in levels of tumor-derived monoclonal 
Ig (M spike) in patients with asymptomatic plasmaproliferative diseases 
with or without detectable SOX2-specifi  c T cells. (B) Comparison of time-
to-progression Kaplan-Meier’s curves constructed for the cohorts with 
and without SOX2-specifi  c T cells (P < 0.01 using the log-rank test). 838  IMMUNITY TO STEM CELLS IN PREMALIGNANCY | Spisek et al.
  immunity did not develop any clinical autoimmunity. These 
considerations make SOX2 an attractive target for specifi  c 
immunotherapy of MM.
The potential role of the immune system in regulating 
cancer development has been extensively debated (1, 23). It 
is likely that distinct components of the immune system have 
the capacity to both promote as well as suppress cancer. It is 
therefore of interest that T cell immunity to SOX2 correlates 
with a favorable outcome. Antibodies against SOX2 have 
also been detected in some patients with small cell lung   
cancer and impart a favorable prognosis, although SOX2-
specifi  c T cells have not yet been studied in these patients 
(24, 25). However, the correlation of SOX2 immunity with 
a favorable outcome does not establish a causal relationship. 
For example, the detection of SOX2-specifi  c T cells may be 
refl  ective of altered biology of tumor progenitors in MGUS 
versus MM. Therefore, clinical studies to enhance SOX2 
  immunity are needed to directly assess whether immunity to 
SOX2 or other antigens on tumor progenitors can induce 
tumor regressions in patients with MM and other cancers. 
These data should also encourage a systematic search for spe-
cifi  c targets of spontaneous T cell immunity in other human 
preneoplastic states.
These data also have several clinical implications. Current 
management of patients with asymptomatic plasmaprolifera-
tive tumors is a challenge, as it is often diffi   cult to predict dis-
ease progression and the need for therapy in these patients 
(26). These data suggest that in addition to changes in tumor 
cells, the nature of tumor-specifi  c host immune response may 
also provide a novel approach for predicting an outcome. 
Most studies of immunotherapy of human cancer to date 
have focused on trying to target antigens expressed by bulk 
tumors. This approach has led to generally low rates of clini-
cal regressions, often in spite of high frequencies of immunity 
to vaccine antigens. These data suggest the possibility that 
targeting drugs or the immune system against targets critical 
to the biology of tumor progenitors may be needed for the 
eff  ective control of cancer.
MATERIALS AND METHODS
Patient samples. Bone marrow and peripheral blood samples used in this 
study were obtained from patients with a diagnosis of MGUS, AMM, and 
MM based on standard clinical criteria (27). All patients signed an informed 
consent approved by the institutional review board. Several samples were 
obtained under the auspices of a prospective multicenter Southwest Oncol-
ogy Group observational clinical trial (S0120) of patients with asymptomatic 
plasmaproliferative disorders.
Cell lines and media. Multiple MM cells lines U266 and cag have been 
previously described (28). For DC and T cell cultures, 5% pooled human 
  serum (Labquip) was used.
SADA for analyzing serum reactivity. Preabsorbed serum samples from 
28 patients with MGUS, 14 patients with AMM, 35 patients with MM, and 
27 healthy blood donors were evaluated by SADA for the presence of IgG 
antibody to a panel of 83 SEREX-defi  ned antigens, as previously described 
(29). In brief, precut nitrocellulose membranes (80 × 120 mm) were pre-
coated with a layer (≈0.2 mm) of growth media and placed on a reservoir 
layer of media in Omni Tray (86 × 128 mm; Nalge Nunc International 
Corp.). A total of 105 PFU of bacteriophage-encoding individual SEREX-
defi  ned tumor antigens (Table S1) in a volume of 20 μl was mixed with 
20 μl of exponentially growing Escherichia coli XL-1 Blue MRF′ and spotted 
on the precoated nitrocellulose membranes. 30 SEREX-defi  ned  antigens 
were spotted in duplicate on each nitrocellulose membrane. Membranes were 
incubated for 15 h at 37°C and processed as per the standard SEREX protocol 
(29). In brief, membranes were blocked in 0.5% nonfat dried milk, incubated 
in 10 ml of a 1:200 dilution of sera at room temperature for 15 h, and incu-
bated in a 1:3,000 dilution of alkaline phosphatase–conjugated, Fc fragment–
specifi  c, goat anti–human IgG (Jackson ImmunoResearch Laboratories). 
Serum IgG reactivity was detected with the alkaline phosphatase substrate 
4-nitro blue tetrazolium chloride/5-bromo-4-chloro-3-indolyl-phosphate 
(Biosource International). Positive assays were repeated in a blinded   manner 
to confi  rm reactivity.
ELISA for the detection of anti-SOX2, EBV (EBNA-1) antibodies. 
Sera were screened for the presence of anti-SOX2 antibodies by standard 
ELISA. A 96-well microtiter polystyrene half-area immunoassay plate 
(Corning) was coated in PBS with 1 μg/ml of recombinant human SOX2 
protein overnight at 4°C. Plates were washed with PBS and blocked with 
5% nonfat dry milk in PBS for 2 h. After washing, serum samples at 1:100 
and 1:400 dilutions in the blocking solution were added and incubated for 
1 h at room temperature. Plates were extensively washed with 0.05% Tween 
20 in PBS, and the secondary antibody, horseradish peroxidase–labeled goat 
anti–human IgG, IgG1, IgG2, IgG3, or IgG4 (Southern Biotechnology As-
sociates, Inc.), in blocking solution was added. Plates were incubated for 1 h 
at room temperature and washed, and SOX2 reactivity was revealed by the 
addition of substrate solution (Biosource International). After 30 min of in-
cubation in the dark, the reaction was ended with Stop solution (Biosource 
International), and the absorbance at 450 nm was measured using an ELISA 
plate reader (MultiSkan Plus; Thermo Fisher Scientifi  c). The threshold for 
seropositivity for SOX2 antibodies was determined as ODN450 at 0.11, 
based on the mean background for no antigen controls plus 4 SD. Sero-
positivity for anti–EBNA-1 IgG was determined using a commercial kit 
(SCIMEDX) according to the manufacturer’s instructions. Samples with an 
antibody index ≥1 were considered to be seropositive for EBNA IgG.
Detection of cytokines by ELISA. Commercial ELISA kits (Biosource 
International) were used to measure IFN-γ, IL-4, and IL-10 concen-
trations in the cell-culture supernatants, according to the manufac-
turer’s recommendations.
Preabsorption of anti-SOX2–positive samples. Before ELISA analysis 
for SOX2 reactivity, samples with anti-SOX2 IgGs were preabsorbed over-
night at 4°C in 96-well plates previously coated with 30 μg/ml of recombi-
nant SOX2 protein and blocked with 5% nonfat dry milk in PBS.
Synthesis of the SOX-2 peptide library. Peptides were synthesized in 
collaboration with the Proteomics Resource Center at the Rockefeller Uni-
versity. Overlapping sequences from the Sox-2 protein were determined and 
optimized for synthesis by using the epitope library fragment generation pro-
gram PeptGen, developed by Los Alamos National Laboratories, as part of 
the HIV Immunology Database (available at http://www.hiv.lanl.gov). All 
peptides were created in a microtiter plate (96 well) format using a parallel 
peptide synthesizer/spotter (MultiPep; Intavis) on resin (TentaGel R RAM; 
Rapp Polymere) loaded at 5 μm per well, using Fmoc-protected amino 
  acids (Anaspec). Deprotection of the amine was accomplished with 20% 
  piperidine (Sigma-Aldrich) in N-methylpyrrolidinone (NMP; EMD Bio-
sciences, Inc.). Repetitive coupling reactions were conducted using 0.3 M 
HATU/ HOBt and 0.4 M NMM using NMP as the primary solvent. Simul-
taneous resin cleavage and side-chain deprotection were achieved by 
  treatment with 0.8 ml/well of concentrated, sequencing grade trifl  uoroacetic 
acid (Fisher Scientifi  c) with triisopropylsilane, water, and DODT in a ratio 
of 95:2:2:1 for 2 h. After vacuum fi  ltration to a collection plate, centrifugal 
evaporation (Genevac) was used to remove TFA from the plate containing JEM VOL. 204, April 16, 2007  839
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the soluble peptides. Peptides were treated with 8 M acetic acid, and the 
acidic mixture was evaporated and redissolved in 20% acetonitrile and HPLC 
(Waters Chromatography)-grade water and dried twice more. All crude 
products were subsequently analyzed by reversed-phase HPLC using a C18 
column (Chromolith Performance; Merck). Individual peptide integrity was 
verifi  ed by matrix-assisted laser desorption/ionization (MALDI) mass spectro-
metry using a delayed extraction spectrometer system (Voyager; PerSeptive/
Applied Biosystems).
Screening for SOX2-reactive T cells in fresh PBMCs. MNCs from 
blood or bone marrow were separated by density gradient centrifugation us-
ing Ficoll-Hypaque (GE Healthcare). 2 × 105 PBMCs or BMMCs in 200 μl 
of media were cultured in the presence of 2.5 μg/ml of peptide pools de-
rived from the SOX2 peptide library or with a mixture of MHC class I–
  restricted peptides derived from CMV, EBV, and infl  uenza virus (CEF mix) 
(30). The composition of the SOX2 peptide library pools is noted in Table 
S3. After 48 h, supernatants were collected and assayed for the production of 
IP-10 by Luminex, using the manufacturer’s directions (Upstate Biotech-
nology), and analyzed by Beadview software (Upstate Biotechnology). 
In some experiments, CD3 T cells were depleted by negative selection, 
or PBMC stimulation by specifi  c antigens was performed in the presence of 
IFN-γ or anti–MHC class I blocking mAbs (Biolegend) to confi  rm the 
specifi  city of IP-10 production. For some experiments, CD138+ and 
CD138− fractions of U266 (HLA-A2+ cell line) were also used for the stim-
ulation of fresh PBMCs from HLA-A2+ MGUS patients with documented 
anti-SOX2 T cell reactivity, and IP-10 production was analyzed by Luminex 
48 h later. A twofold or greater increase in IP-10 production relative to con-
trol was considered as positive for the presence of antigen-specifi  c T cells.
DC generation and expansion of SOX2-specifi  c T cells. MNCs from 
blood or bone marrow were separated by density gradient centrifugation us-
ing Ficoll-Hypaque. DCs were generated from monocytes isolated by CD14 
magnetic beads (Miltenyi Biotec) and cultured for 5 d in the presence of 
GM-CSF (Immunex) and IL-4 (R&D Systems), as previously described (30). 
Day-5 DCs were matured overnight with 100 ng/ml LPS (Sigma-Aldrich) 
and pulsed for 2 h with peptide pools derived from the SOX2 peptide 
library (15-mer peptides overlapping by 11 aa) at 2 μg/ml. A CD14− 
T cell–enriched fraction was added to a U-bottom 96-well plate at 2 × 105 
cells/well in 200 μl of medium and stimulated with mature peptide-pulsed 
DCs at a ratio of 1 DC per 20 CD14− cells. Recombinant IL-2 was added 
at 15 U/ml every third day. Antigen-specifi  c T cells were restimulated with 
the same antigen-pulsed DCs every week and tested for IFN-γ production 
at the time of restimulation by intracellular cytokine fl  ow cytometry.
Flow cytometry for the detection of intracellular cytokines. Anti-
gen-specifi  c cells were analyzed by a fl  ow cytometry–based assay for the de-
tection of intracellular cytokines, as described previously (31). In brief, blood 
or bone marrow T cells were cultured for 12 h with autologous unpulsed 
mature DCs, or DCs loaded with specifi  c peptide mixtures, in the presence 
of Golgistop (Cytofi   x/CytoPerm Plus Kit; BD Biosciences). Cells were 
fi  xed and permeabilized in 100 μl Cytofi  x/Cytoperm solution using the 
manufacturer’s instructions and stained for intracellular cytokines (IFN-γ) 
and surface markers (CD3 and CD8).
Intranuclear SOX2 staining. 5 × 105 cells were fi  xed in Cytofi  x/Cyto-
perm overnight at 4°C. Cells were permeabilized in Cytoperm solution, 
  refi  xed in Cytofi  x/Cytoperm for 5 min on ice, and treated with 300 μg/ml 
DNase I for 45 min at 37°C. Cells were stained with PE-SOX2 mAb (R&D 
Systems) for 20 min at room temperature, washed, and stained for surface or 
intracellular markers. Samples were acquired on an instrument (FACSCali-
bur; BD Biosciences) using CellQuest software (BD Biosciences) and ana-
lyzed with FlowJo software (TreeStar Inc.). Typically, 1–5 × 105 events 
were collected per sample.
Cell sorting and analysis of SOX2 mRNA by TaqMan. CD138− and 
CD138+ fractions of the U266 and cag cell lines were sorted on a FACSVan-
tage (BD Biosciences). The purity of sorted populations used in real-time 
PCR experiments exceeded 95%. RNA was isolated with the RNeasy Mini 
Kit (QIAGEN), and RT-PCR was conducted with the Assays-on-Demand 
(Applied Biosystems) primer probe for SOX2 using a sequence detection 
system (ABI PRISM 7700; Applied Biosystems). Expression of GAPDH was 
monitored as a housekeeping gene. Reactions were set up in triplicates using 
EZ PCR Core Reagents (Applied Biosystems), according to the manufac-
turer’s instructions, with 20 ng of total RNA. The relative expression of 
target genes was calculated using the comparative threshold cycle method.
Clonogenic assays on primary tumor cells. Bone marrow MNCs 
(BMMNCs) were isolated from marrow samples using density gradient cen-
trifugation. CD138+ and CD138– fractions were isolated using CD138 
  microbeads (Miltenyi Biotec), and the CD138– fraction was further depleted 
of normal hematopoietic progenitors using CD34 microbeads (Miltenyi Bio-
tec). CD138−CD34− cells were incubated overnight with SOX2 or control 
peptides and plated (5 × 105 cells/ml) with monocyte-derived DCs at a ratio 
of 1:2 in methylcellulose containing 5% leukocyte-conditioned media 
(Methocult; Stem Cell Technologies, Inc.), as described previously (9). Cells 
were plated in 35-mm2 tissue culture dishes in triplicates and incubated 
at 37°C and 5% CO2. Colonies consisting of >40 cells were counted by 
  microscopy 2–3 wk after plating.
Statistical analysis. Diff  erences in frequencies were assessed with Fisher’s 
exact test for two groups and the χ2 test for three or more groups. Diff  erences 
in change in M protein over time between those with and without SOX2 
immunity were tested using the Wilcoxon test. The criteria for disease pro-
gression required an increase in M protein ≥0.5 g/dl, an increase in marrow 
plasmacytosis ≥10%, or a development of symptomatic disease requiring ini-
tiation of therapy (32). Progression-free survival curves were constructed us-
ing the Kaplan-Meier method (33) and tested using the log-rank test (34).
Online supplemental material. Table S1 provides a list of tumor 
antigens tested in the SADA. Table S2 shows a list of tumor antigens 
  inducing IgG antibody responses in patients with plasma cell diseases. 
  Table S3 provides the sequences of peptides used in the SOX2 peptide 
library. Online supplemental material is available at http://www.jem
.org/cgi/content/full/jem.20062387/DC1.
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